Compare
Werewolf Therapeutics, Inc. vs Context Therapeutics Inc. vs Corvus Pharmaceuticals, Inc. vs Incannex Healthcare Inc.
| Latest fiscal year | Werewolf Therapeutics, Inc. HOWL | Context Therapeutics Inc. CNTX | Corvus Pharmaceuticals, Inc. CRVS | Incannex Healthcare Inc. IXHL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$60.82M | -$36.12M | -$15.28M | -$19.30M |
| EPS (Diluted) | -$1.33 | -$0.38 | -$0.53 | -$1.66 |
| Operating cash flow | -$60.29M | -$26.39M | -$32.80M | -$12.87M |
| Free cash flow | -$60.29M | -$26.42M | -$32.97M | -$12.88M |
| Cash & equivalents | $57.05M | $66.00M | $4.58M | $67.71M |
| Total assets | $69.40M | $68.49M | $71.12M | $72.98M |
| Total liabilities | $44.59M | $8.02M | $9.91M | $5.61M |
| Shareholders' equity | $24.80M | $60.47M | $61.20M | $67.37M |
| Return on year-end equity | -245.2% | -59.7% | -25.0% | -28.6% |
| Shares outstanding | 48.60M | 91.88M | 74.70M | 12.54M |
Revenue, most recent five fiscal years
| Fiscal year | Werewolf Therapeutics, Inc. | Context Therapeutics Inc. | Corvus Pharmaceuticals, Inc. | Incannex Healthcare Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $0 Ended 2026-06-30 |
| 1 year earlier | n/a | n/a | n/a | $86.0K Ended 2025-06-30 |
| 2 years earlier | n/a | n/a | n/a | $12.0K Ended 2024-06-30 |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |